


Amendment to the Claims

1. (Cancelled)
1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
11. (Currently Amended) A ~~An apoptosis-inducing~~ compound selected from
 - 4-(9-adeninyl)-2-cyclopenten-1-one,
 - 4-(9-guaninyl)-2-cyclopenten-1-one,
 - 1,5-epoxy-1-hydroxy-3-penten-2-one,
 - 2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl) -1,3-dioxolane, andthe compound represented by the following formula [I]



[I]

(In the formula, R is a residual group after removal of an SH group from an amino acid containing an SH group or a peptide containing an amino acid containing an SH group.)

12. (Currently Amended) A pharmaceutical agent ~~for therapy of cancer~~ characterized in that said pharmaceutical agent contains a compound selected from

~~4,5-dihydroxy-2-pentenal,~~

~~4-hydroxy-2-cyclopenten-1-one,~~


4 (9-adeninyl)-2-cyclopenten-1-one,

4-(9-guaninyl)-2-cyclopenten-1-one,

2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl)-1,3-dioxolane,

1,5-epoxy-1-hydroxy-3-penten-2-one, and

a compound represented by the formula [I] as an effective component



(In the formula, R is a residual group after removal of an SH group from an amino acid containing an SH group or a peptide containing an amino acid containing an SH group).

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Currently Amended) A pharmaceutical agent for therapy of rheumatism, characterized in that said pharmaceutical agent contains a compound selected from 4,5-dihydroxy-2-pentenal, 4-hydroxy-2-cyclopenten-1-one, 2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl), 3-dioxolane, and 4(9-guaninyl)-2-cyclopenten-1-one as the effective component.

28. (Un-amended) A pharmaceutical agent for therapy of a disease selected from the group consisted of systemic hypotension, lowering in blood pressure response, autoimmune disease, inflammation, arthritis, rheumatic arthritis, diabetes mellitus, inflammatory intestine diseases, insufficiency of blood vessel function, etiological dilation of blood vessel, damages of tissues, cardiovascular ischemia, sensitivity to pain, cerebral ischemia, and diseases caused by angiogenesis characterized in that, said pharmaceutical agent contains 2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl)1,3-dioxolane as an effective component

29. (Cancelled)